India Thrombolytic Therapy Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Thrombolytic Therapy Market was valued at USD 556.0 million in 2025 and is projected to reach USD 830.51 million by 2032, growing at a CAGR of approximately 5.9% during 2026–2032.
India Thrombolytic Therapy Market Highlights
| Report Metric | Details |
| Report Name | India Thrombolytic Therapy Market |
| Market Size 2025 | USD 556.0 million |
| Market Size 2032 | USD 830.51 million |
| Absolute Growth 2025–2032 | USD 274.51 million |
| CAGR 2026–2032 | 5.9% |
| Peak Annual Growth | 8.5% in 2030 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Drug Type, 2025 | tPA (Alteplase) (46% share) |
| Leading Delivery Method, 2025 | IV Infusion (41% share) |
| Leading Application Indication, 2025 | Acute Stroke (36% share) |
| Leading End User, 2025 | Hospitals (48% share) |
| Fastest-Growing Drug Type | Tenecteplase (7.8% CAGR) |
| Fastest-Growing Delivery Method | Single Bolus (7.4% CAGR) |
| Fastest-Growing Application Indication | Pulmonary Embolism (8.3% CAGR) |
| Fastest-Growing End User | Cardiac Centers (7.9% CAGR) |
| Growing Sector | hospitals |
| Key End Users | hospitals, cardiac centers, emergency services, critical care units |
India Thrombolytic Therapy Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The table below sets out the estimated growth rate for each year and the main factor behind it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 6.4 | The market saw steady demand from hospitals due to increased myocardial infarction cases. |
| 2023 | 3.4 | Growth slowed as hospitals adjusted to new treatment protocols and training needs. |
| 2024 | 7.1 | Demand accelerated with the implementation of the National Stroke Program in hospitals. |
| 2025 | 7.4 | A surge in acute stroke cases drove higher adoption rates of thrombolytic therapy. |
| 2026 | 4.0 | Growth slowed as hospitals faced challenges in training staff for new protocols. |
| 2027 | 5.6 | Increased awareness of thrombolytic therapy benefits boosted demand among healthcare providers. |
| 2028 | 3.6 | The market experienced a slowdown as hospitals faced resource allocation issues. |
| 2029 | 5.3 | Demand rose as cardiac centers expanded their emergency service capabilities. |
| 2030 | 8.5 | A significant increase in acute stroke cases led to peak growth in thrombolytic therapy usage. |
| 2031 | 7.9 | Growth slowed as hospitals faced procurement delays for thrombolytic agents. |
| 2032 | 6.5 | Demand stabilised as hospitals adapted to new treatment guidelines and protocols. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Thrombolytic Therapy Market Synopsis
Thrombolytic Therapy in India involves using drugs to dissolve blood clots obstructing blood vessels, primarily for treating myocardial infarction and acute strokes. This therapy is made from recombinant DNA technology or bacterial sources. The India Thrombolytic Therapy Market is expanding due to rising healthcare needs, particularly in hospitals and cardiac centres. With approximately 1.5 million myocardial infarction cases reported annually, demand is driven by emergency services and healthcare investments. The National Health Mission's initiatives further promote the adoption of thrombolytic therapy across the country.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Rising cases of myocardial infarction and acute strokes drive demand for thrombolytic therapy. | Driver | High | Acute Stroke |
| Increased funding for emergency medical services enhances access to thrombolytic therapy. | Driver | High | Emergency Services |
| Investment in training healthcare professionals creates opportunities for improved therapy administration. | Opportunity | High | Hospitals |
| Expansion of cardiac centers in metropolitan areas opens new markets for thrombolytic therapy. | Opportunity | Medium | Cardiac Centers |
| Challenges in staff training and resource allocation can hinder effective therapy delivery. | Restraint | High | Hospitals |
| Procurement delays for thrombolytic agents can impact availability in emergency situations. | Restraint | Medium | Emergency Services |
| Limited awareness among healthcare providers can slow market growth. | Challenge | High | Critical Care Units |
| Regulatory hurdles in drug approvals can delay access to new thrombolytic agents. | Challenge | Medium | Hospitals |
Evaluation of Drivers in India Thrombolytic Therapy Market (2026–2032)
The main growth drivers and the segments they affect most are set out below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increasing myocardial infarction cases drive demand for thrombolytic agents. | Streptokinase | With approximately 1.5 million cases annually, hospitals are purchasing more thrombolytics for treatment. |
| Government funding for emergency medical services improves access to thrombolytics. | IV Infusion | In 2023, ₹500 crores were allocated to upgrade emergency medical services, increasing availability. |
| Growing awareness of thrombolytic therapy benefits encourages hospitals to adopt it. | tPA (Alteplase) | The inclusion of tPA in the Essential Medicines List promotes its use in emergency care. |
| Training initiatives for healthcare professionals support effective thrombolytic therapy administration. | Tenecteplase | The National Health Mission's funding scheme aims to improve training, leading to higher usage. |
| Expansion of cardiac centers in urban areas increases demand for thrombolytic therapy. | Cardiac Centers | The average population served by a cardiac center is around 500,000, driving demand for services. |
The Thrombolytic Therapy market in India is growing on the back of rising cases of myocardial infarction and acute strokes, alongside increased funding for emergency medical services. Approximately 1.5 million myocardial infarction cases reported annually drive hospitals to purchase more thrombolytic agents. In 2023, ₹500 crores were allocated to upgrade emergency services, improving access to therapy. The inclusion of tPA in the Essential Medicines List promotes its use in emergency care.
Evaluation of Restraints in India Thrombolytic Therapy Market
The key brakes on demand, and where they bite hardest, are shown below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Staff training challenges can hinder effective thrombolytic therapy delivery. | Hospitals | Inadequate training resources can delay the implementation of new protocols, affecting patient care. |
| Procurement delays for thrombolytic agents impact availability in emergencies. | Emergency Services | Supply chain issues can lead to shortages, delaying treatment for critical patients. |
| Limited awareness among healthcare providers can slow market growth. | Critical Care Units | Insufficient education on thrombolytic therapy benefits may result in underutilisation. |
| Regulatory hurdles in drug approvals can delay access to new thrombolytic agents. | Hospitals | Lengthy approval processes can slow the introduction of new therapies. |
| Resource allocation issues in hospitals may affect therapy availability. | Cardiac Centers | Budget constraints can limit the procurement of necessary thrombolytic agents. |
India Thrombolytic Therapy Market Challenges
In the India thrombolytic therapy market, producers encounter fierce competition from both local and global manufacturers, which drives down prices and reduces profit margins for suppliers. Importers face high regulatory approval costs due to stringent requirements from the Drug Controller General of India, resulting in delays that can increase operational expenses for distributors. Skills shortages in rural healthcare facilities hinder the effective administration of thrombolytics, potentially delaying treatment for around 1.5 million patients with myocardial infarction each year. Buyers, especially hospitals in metropolitan areas, struggle with the high costs of advanced thrombolytic agents, limiting timely access to critical care for patients in need.
Trends in the India Thrombolytic Therapy Market
Below mentioned are some of the trends shaping the India Thrombolytic Therapy Market growth.
- Shift Towards Improved Emergency Medical Services: India is improving emergency medical services to increase thrombolytic therapy access. The National Health Mission's allocation of ₹500 crores in 2023 aims to upgrade facilities nationwide, resulting in faster treatment for patients.
- Increased Adoption of tPA for Acute Stroke Treatment: The inclusion of tPA in the Essential Medicines List has led to its increased adoption in hospitals. In 2022, hospitals reported a rise in tPA usage for acute stroke cases, reflecting a growing recognition of its effectiveness.
- Focus on Training Healthcare Professionals: Healthcare facilities are prioritising training for staff in thrombolytic therapy administration. The National Health Mission's funding scheme initiated in 2020 aims to improve skills, ensuring timely and effective treatment for patients.
- Growth of Cardiac Centers in Urban Areas: Urban areas are seeing a rise in cardiac centers, improving access to thrombolytic therapy. The average population served by these centers is around 500,000, driving demand for advanced cardiac care.
Investment Opportunities in the India Thrombolytic Therapy Market
The following opportunities in the India Thrombolytic Therapy Market pair current demand with a clear way in.
- Investment in Emergency Medical Services: Upgrading emergency medical services presents an opportunity now, with ₹500 crores allocated in 2023. Hospitals and cardiac centres can invest in new equipment and training to improve thrombolytic therapy delivery.
- Supply of Advanced Thrombolytic Agents: The increasing demand for innovative thrombolytic agents creates a timely opportunity. Hospitals are looking for effective solutions, particularly for acute stroke treatment, to improve patient outcomes.
- Expansion of Cardiac Centers: The growth of cardiac centres in metropolitan areas offers a chance for investment. With an average population of 500,000 served, establishing new centres can meet rising healthcare demands.
- Training Programs for Healthcare Professionals: There is a pressing need for training programs focused on thrombolytic therapy administration. Hospitals can collaborate with educational institutions to improve staff skills and enhance patient care.
Government Initiatives in the India Thrombolytic Therapy Market
The 'National Stroke Program' launched by the Ministry of Health in 2021 aims to improve access to thrombolytic therapy across India, targeting 1,000 hospitals by 2025. This initiative increases the capacity of healthcare facilities to deliver timely treatment for acute strokes. Additionally, the 'Emergency Medical Services (EMS) Policy' updated in 2022 focuses on improving the delivery of thrombolytic therapy in emergency situations, ensuring that patients receive critical care swiftly. These measures aim to enhance the overall quality of emergency medical services in the country.
The 'Ayushman Bharat' scheme covers thrombolytic therapy for eligible patients in public hospitals. This scheme, effective from 2020, ensures that patients have access to necessary treatments without financial burden. Furthermore, the 'National Health Mission' initiated a funding scheme in 2020 with a budget of ₹200 crores for training healthcare professionals in thrombolytic therapy administration. This funding supports the development of skills and knowledge among providers, improving patient outcomes.
Future Insight of the India Thrombolytic Therapy Market
Several forward-looking factors should support the India thrombolytic therapy market over the coming years. The Indian government's ₹500 crores investment in emergency medical services will improve infrastructure for rapid thrombolytic administration. Advocacy from the Indian Stroke Association is likely to raise awareness and encourage healthcare facilities to adopt thrombolytic therapy protocols. Additionally, the widespread adoption of ISO 9001:2015 standards among healthcare providers will improve quality management practices, leading to better patient outcomes and a more efficient healthcare system.
Market Segmentation Analysis
The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.
By Drug Type – tPA (Alteplase) Dominated, Tenecteplase Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, tPA (Alteplase) took a 46% share of drug type in 2025, more than any other category. tPA (Alteplase) commands the largest market share in India due to its widespread use in treating acute strokes. Hospitals depend on this agent to manage approximately 1.5 million myocardial infarction cases reported annually, highlighting its critical role in emergency care. The quickest growth will come from Tenecteplase, forecast to expand at a CAGR of 7.8% between 2026 and 2032. Tenecteplase is rapidly gaining traction because of its user-friendly administration, appealing to healthcare providers. The growing advocacy from the Indian Stroke Association for thrombolytics in acute stroke management is likely to further accelerate its adoption. Suppliers should prioritise the availability of Tenecteplase to cater to the increasing demand in emergency medical settings.
By Delivery Method – IV Infusion Dominated, Single Bolus Expected to Grow Fastest
In 2025, IV Infusion led the delivery method split with a 41% share. IV Infusion remains the leading delivery method for thrombolytic therapy as it is the standard approach for administering these critical medications. Hospitals across metropolitan areas have adopted this method due to its proven efficacy in emergency situations. Single Bolus is set to record the highest CAGR in this split, 7.4% over 2026–2032. Single Bolus is gaining traction as the fastest delivery method for certain thrombolytic agents, offering quicker administration times. The average target time for administering thrombolytics in emergency services is under 60 minutes, which aligns with this method's advantages. Buyers should consider integrating Single Bolus methods to improve response times in emergency care.
By Application Indication – Acute Stroke Dominated, Pulmonary Embolism Expected to Grow Fastest
The largest application indication category in 2025 was Acute Stroke, with a 36% share of total revenue. Acute Stroke holds the largest market share in thrombolytic therapy as it addresses a critical health issue, with approximately 1.5 million cases of myocardial infarction reported annually in India. The support from the National Health Mission for promoting thrombolytics in rural healthcare facilities highlights its essential role in the healthcare landscape. Over 2026–2032, Pulmonary Embolism is expected to post the fastest growth, at a CAGR of 8.3%. Pulmonary Embolism is witnessing the fastest growth due to increased recognition of its importance in emergency medicine. The Indian Stroke Association's advocacy for thrombolytics in acute stroke management is likely to further enhance awareness and usage in this area. This indicates that suppliers should focus on developing and promoting thrombolytic therapies specifically for Pulmonary Embolism to capture this expanding market.
By End User – Hospitals Dominated, Cardiac Centers Expected to Grow Fastest
With a 48% revenue share in 2025, Hospitals was the largest end user category. Hospitals dominate the thrombolytic therapy market as the primary end-users, providing essential emergency medical services to the population. The average population served by each cardiac center, around 500,000, underscores the reliance on hospitals for acute care. Cardiac Centers are projected to grow fastest, at a CAGR of 7.9% during 2026–2032. Cardiac Centers are the fastest-growing end-user segment, driven by their specialised focus on cardiac care and the increasing demand for advanced treatment options. The Indian government's investment of ₹500 crores in upgrading emergency medical services will likely enhance the capabilities of these centres. This suggests that suppliers should strategically target Cardiac Centers to meet the rising demand for specialised thrombolytic therapies.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Thrombolytic Therapy Market Outlook
- Market Size of India Thrombolytic Therapy Market, 2025
- Forecast of India Thrombolytic Therapy Market, 2032
- Historical Data and Forecast of India Thrombolytic Therapy Revenues & Volume for the Period 2022 - 2032F
- India Thrombolytic Therapy Market Trend Evolution
- India Thrombolytic Therapy Market Drivers and Challenges
- India Thrombolytic Therapy Price Trends
- India Thrombolytic Therapy Porter's Five Forces
- India Thrombolytic Therapy Industry Life Cycle
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Drug Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By tPA (Alteplase) for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Streptokinase for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Tenecteplase for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Reteplase for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Delivery Method for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By IV Infusion for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Intravenous Injection for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Single Bolus for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Multiple Bolus for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Application Indication for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Acute Stroke for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Myocardial Infarction for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Pulmonary Embolism for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Arterial Blockage for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Cardiac Centers for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Critical Care Units for the Period 2022 - 2032F
- Historical Data and Forecast of India Thrombolytic Therapy Market Revenues & Volume By Emergency Services for the Period 2022 - 2032F
- India Thrombolytic Therapy Import Export Trade Statistics
- Market Opportunity Assessment By Drug Type
- Market Opportunity Assessment By Delivery Method
- Market Opportunity Assessment By Application Indication
- Market Opportunity Assessment By End User
- India Thrombolytic Therapy Top Companies Market Share
- India Thrombolytic Therapy Competitive Benchmarking By Technical and Operational Parameters
- India Thrombolytic Therapy Company Profiles
- India Thrombolytic Therapy Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments.
By Drug Type
- tPA (Alteplase)
- Streptokinase
- Tenecteplase
- Reteplase
By Delivery Method
- IV Infusion
- Intravenous Injection
- Single Bolus
- Multiple Bolus
By Application Indication
- Acute Stroke
- Myocardial Infarction
- Pulmonary Embolism
- Arterial Blockage
By End User
- Hospitals
- Cardiac Centers
- Critical Care Units
- Emergency Services
